{"id":588593,"date":"2022-02-28T12:52:01","date_gmt":"2022-02-28T12:52:01","guid":{"rendered":"https:\/\/www.abnewswire.com\/pressreleases\/?p=588593"},"modified":"2022-02-28T12:52:01","modified_gmt":"2022-02-28T12:52:01","slug":"epithelioid-sarcoma-market-epidemiology-pipeline-therapies-key-companies-and-competitive-analysis-by-delveinsight","status":"publish","type":"post","link":"https:\/\/www.abnewswire.com\/pressreleases\/epithelioid-sarcoma-market-epidemiology-pipeline-therapies-key-companies-and-competitive-analysis-by-delveinsight_588593.html","title":{"rendered":"Epithelioid Sarcoma Market, Epidemiology, Pipeline, Therapies, Key Companies and Competitive Analysis by DelveInsight"},"content":{"rendered":"<div style=\"float:right; width:250px; padding:8px 10px 10px 10px;\">\n<div><a href=\"https:\/\/www.abnewswire.com\/uploads\/1646023391.jpeg\" style=\"border:none !important;\" target=\"_blank\" rel=\"nofollow\" ><img loading=\"lazy\" decoding=\"async\" class=\"alignnone size-medium wp-image-29\" title=\"Epithelioid Sarcoma Market, Epidemiology, Pipeline, Therapies, Key Companies and Competitive Analysis by DelveInsight\" src=\"https:\/\/www.abnewswire.com\/uploads\/1646023391.jpeg\" alt=\"Epithelioid Sarcoma Market, Epidemiology, Pipeline, Therapies, Key Companies and Competitive Analysis by DelveInsight\" width=\"225\" height=\"225\" style=\"padding:0px 0px 10px 10px; border:0 solid !important;\" \/><\/a><\/div>\n<div class=\"quotes\">\n<div>Epithelioid Sarcoma Market<\/div>\n<\/div>\n<\/div>\n<p style=\"text-align: justify;\">Epithelioid sarcoma&nbsp;is a rare, malignant, slow-growing type of soft-tissue cancer. It begins as a slow growing, firm lump in the deep soft tissue or skin of arms, hands and fingers. It also occurs in legs, neck, and head. The lumps are usually painless, but sometimes this sarcoma appears as ulcers which don&rsquo;t even heal. It tends to have a high recurrence rate.<\/p>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\">DelveInsight&rsquo;s&nbsp;&ldquo;<strong><a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/report-store\/epithelioid-sarcoma-market?utm_source=SatPR&amp;utm_medium=pressrelease&amp;utm_campaign=apr\">Epithelioid Sarcoma Market<\/a>&nbsp;Insights, Epidemiology, and Market Forecast-2032<\/strong>&Prime;&nbsp;report delivers an in-depth understanding of the Epithelioid Sarcoma, historical and forecasted epidemiology as well as the Epithelioid Sarcoma market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.<\/p>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\"><strong>Some facts of&nbsp;<a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/report-store\/epithelioid-sarcoma-market?utm_source=SatPR&amp;utm_medium=pressrelease&amp;utm_campaign=apr\">Epithelioid Sarcoma Market<\/a>&nbsp;are:<\/strong><\/p>\n<ul style=\"text-align: justify;\">\n<li>Epithelioid sarcoma is a mesenchymal soft tissue sarcoma often arising in the extremities, usually in young adults with a pick of incidence at 35&thinsp;years of age.<\/li>\n<li>The Epithelioid sarcoma incidence rate is 0.03\/100,000 in the European Union and 0.05\/10,000 in the USA as per RARECAREnet and the SEER18 cancer registries.<\/li>\n<li>Epithelioid sarcomas are rare, representing less than 1% of soft tissue sarcomas, and have a predilection for men (up to 2:1 male to female ratio). Most reported tumors occur in young males ranging in age from 10 to 45 years. The extremes of ages include ages 4 to 90, with a median age of 27 years.<\/li>\n<\/ul>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\"><strong>Request for Sample Report:&nbsp;<a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/sample-request\/epithelioid-sarcoma-market?utm_source=SatPR&amp;utm_medium=pressrelease&amp;utm_campaign=apr\">https:\/\/www.delveinsight.com\/sample-request\/epithelioid-sarcoma-market<\/a><\/strong><\/p>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\"><strong>Scope of&nbsp;Epithelioid Sarcoma Market Report:<\/strong><\/p>\n<ul style=\"text-align: justify;\">\n<li>The report covers the descriptive overview of Epithelioid Sarcoma, explaining its causes, signs and symptoms, pathophysiology, diagnosis and currently available therapies<\/li>\n<li>Comprehensive insight has been provided into the Epithelioid Sarcoma epidemiology and treatment in the 7MM<\/li>\n<li>Additionally, an all-inclusive account of both the current and emerging therapies for Epithelioid Sarcoma is provided, along with the assessment of new therapies, which will have an impact on the current treatment landscape<\/li>\n<li>A detailed review of the Epithelioid Sarcoma market; historical and forecasted is included in the report, covering drug outreach in the 7MM<\/li>\n<li>The report provides an edge while developing business strategies, by understanding trends shaping and driving the global Epithelioid Sarcoma market<\/li>\n<\/ul>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\"><strong>Some of&nbsp;Epithelioid Sarcoma Companies&nbsp;in Market are:<\/strong><\/p>\n<ul style=\"text-align: justify;\">\n<li>Epizyme, Inc.<\/li>\n<li>Analysis Group, In<\/li>\n<li>WEP Clinical<\/li>\n<li>Amgen<\/li>\n<li>Merck Sharp &amp; Dohme Corp.<\/li>\n<li>And Others<\/li>\n<\/ul>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\"><strong>Request for Sample Report:&nbsp;<a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/sample-request\/epithelioid-sarcoma-market?utm_source=SatPR&amp;utm_medium=pressrelease&amp;utm_campaign=apr\">https:\/\/www.delveinsight.com\/sample-request\/epithelioid-sarcoma-market<\/a><\/strong><\/p>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\"><strong><a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/report-store\/epithelioid-sarcoma-market?utm_source=SatPR&amp;utm_medium=pressrelease&amp;utm_campaign=apr\">Epithelioid Sarcoma Drugs<\/a>&nbsp;are:<\/strong><\/p>\n<ul style=\"text-align: justify;\">\n<li>Tazemetostat<\/li>\n<li>Doxorubicin<\/li>\n<li>Talimogene Laherparepvec<\/li>\n<li>And Many Others<\/li>\n<\/ul>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\"><strong>Table of Contents:<\/strong><\/p>\n<ol style=\"text-align: justify;\" start=\"1\">\n<li>Key Insights<\/li>\n<li>Executive Summary of Epithelioid sarcoma<\/li>\n<li>Competitive Intelligence Analysis for Epithelioid sarcoma<\/li>\n<li>Epithelioid sarcoma: Market Overview at a Glance<\/li>\n<li>Epithelioid sarcoma: Disease Background and Overview<\/li>\n<li>Patient Journey<\/li>\n<li>Epithelioid sarcoma Epidemiology and Patient Population<\/li>\n<li>Treatment Algorithm, Current Treatment, and Medical Practices<\/li>\n<li>Epithelioid sarcoma&nbsp;Unmet Needs<\/li>\n<li>Key Endpoints of Epithelioid sarcoma Treatment<\/li>\n<li>Epithelioid sarcoma&nbsp;Marketed Products<\/li>\n<\/ol>\n<p style=\"text-align: justify;\">List to be continued in report<\/p>\n<ol style=\"text-align: justify;\" start=\"12\">\n<li>Epithelioid sarcoma&nbsp;Emerging Therapies<\/li>\n<\/ol>\n<p style=\"text-align: justify;\">List to be continued in report<\/p>\n<ol style=\"text-align: justify;\" start=\"13\">\n<li>Epithelioid sarcoma: Seven Major Market Analysis<\/li>\n<li>Attribute analysis<\/li>\n<li>7MM: Market Outlook<\/li>\n<li>Access and Reimbursement Overview of Epithelioid sarcoma<\/li>\n<li>KOL Views<\/li>\n<li>Market Drivers<\/li>\n<li>Market Barriers<\/li>\n<li>Appendix<\/li>\n<li>DelveInsight Capabilities<\/li>\n<li>Disclaimer<\/li>\n<\/ol>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\"><strong>About Delveinsight:&nbsp;<\/strong><\/p>\n<p style=\"text-align: justify;\">DelveInsight Business Research is a leading&nbsp;Market Research, and Business Consultant focused purely on Healthcare. It helps pharma companies by providing them with end-to-end services to solve their business problems.<\/p>\n<p><span style='font-size:18px !important;'>Media Contact<\/span><br \/><strong>Company Name:<\/strong> <a href=\"https:\/\/www.abnewswire.com\/companyname\/delveinsight.com_56434.html\" rel=\"nofollow\">DelveInsight Business Research LLP<\/a><br \/><strong>Contact Person:<\/strong> Ankit Nigam<br \/><strong>Email:<\/strong> <a href=\"https:\/\/www.abnewswire.com\/email_contact_us.php?pr=epithelioid-sarcoma-market-epidemiology-pipeline-therapies-key-companies-and-competitive-analysis-by-delveinsight\" rel=\"nofollow\">Send Email<\/a><br \/><strong>Phone:<\/strong> +19193216187<br \/><strong>Address:<\/strong>304 S. Jones Blvd #2432  <br \/><strong>City:<\/strong> Albany<br \/><strong>State:<\/strong> New York<br \/><strong>Country:<\/strong> United States<br \/><strong>Website:<\/strong> <a href=\"https:\/\/www.delveinsight.com\/report-store\/epithelioid-sarcoma-market\" target=\"_blank\" rel=\"nofollow\">https:\/\/www.delveinsight.com\/report-store\/epithelioid-sarcoma-market<\/a><\/p>\n<p><object type=\"text\/html\" data=\"https:\/\/www.delveinsight.com\/report-store\/epithelioid-sarcoma-market\" style=\"width:900px; height:400px;\"><\/object><img decoding=\"async\" src=\"https:\/\/www.abnewswire.com\/press_stat.php?pr=epithelioid-sarcoma-market-epidemiology-pipeline-therapies-key-companies-and-competitive-analysis-by-delveinsight\" alt=\"\" width=\"1px\" height=\"1px\" \/><\/p>\n","protected":false},"excerpt":{"rendered":"<p>Epithelioid Sarcoma Market Epithelioid sarcoma&nbsp;is a rare, malignant, slow-growing type of soft-tissue cancer. It begins as a slow growing, firm lump in the deep soft tissue or skin of arms, hands and fingers. It also occurs in legs, neck, and &hellip; <a href=\"https:\/\/www.abnewswire.com\/pressreleases\/epithelioid-sarcoma-market-epidemiology-pipeline-therapies-key-companies-and-competitive-analysis-by-delveinsight_588593.html\">Continue reading <span class=\"meta-nav\">&rarr;<\/span><\/a><\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[401,435,405,406,404],"tags":[],"class_list":["post-588593","post","type-post","status-publish","format-standard","hentry","category-Business","category-Europe","category-Health-Medicine","category-Pharmaceuticals-Biotech","category-US"],"_links":{"self":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/posts\/588593","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/comments?post=588593"}],"version-history":[{"count":0,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/posts\/588593\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/media?parent=588593"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/categories?post=588593"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/tags?post=588593"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}